UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

Molecular cancer therapeutics, 2011-06, Vol.10 (6), p.1059-1071

2011

Volltextzugriff (PDF)

Src Inhibitors in Metastatic Bone Disease

Clinical cancer research, 2006-10, Vol.12 (20), p.6291s-6295s

2006

Volltextzugriff (PDF)

Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model

Blood, 2004-02, Vol.103 (4), p.1261-1269

2004

Volltextzugriff (PDF)

Structure-Based Design of an Osteoclast-Selective, Nonpeptide Src Homology 2 Inhibitor with in vivo Antiresorptive Activity

Proceedings of the National Academy of Sciences - PNAS, 2000-08, Vol.97 (17), p.9373-9378

2000

Volltextzugriff (PDF)

Future Anti-Catabolic Therapeutic Targets in Bone Disease

Annals of the New York Academy of Sciences, 2006-04, Vol.1068 (1), p.447-457

2006

Volltextzugriff (PDF)

Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

Journal of medicinal chemistry, 2010-06, Vol.53 (12), p.4701-4719

2010

Volltextzugriff (PDF)

9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation

Journal of medicinal chemistry, 2009-08, Vol.52 (15), p.4743-4756

2009

Volltextzugriff (PDF)

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Blood, 2005-07, Vol.106 (1), p.227-234

2005

Volltextzugriff (PDF)

Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases

Kidney international, 2003-06, Vol.63 (S85), p.S2-S5

2003

Volltextzugriff (PDF)

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant

Bioorganic & medicinal chemistry letters, 2011-06, Vol.21 (12), p.3743-3748

2011

Volltextzugriff (PDF)

Src inhibitors: genomics to therapeutics

Expert opinion on investigational drugs, 2001-07, Vol.10 (7), p.1327-1344

2001

Volltextzugriff (PDF)

Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.3623-3623

2010

Volltextzugriff (PDF)

Pharmacologic control of a humanized gene therapy system implanted into nude mice

The Journal of clinical investigation, 1997-12, Vol.100 (11), p.2865-2872

1997

Volltextzugriff (PDF)

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML)

Blood, 2007-11, Vol.110 (11), p.1032-1032

2007

Volltextzugriff (PDF)

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I

Blood, 2006-11, Vol.108 (11), p.2180-2180

2006

Volltextzugriff (PDF)

Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents

Annals of the New York Academy of Sciences, 1991, Vol.614 (1), p.193-213

1991

Volltextzugriff (PDF)

In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT

Blood, 2004-11, Vol.104 (11), p.793-793

2004

Volltextzugriff (PDF)

Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers

Journal of clinical pharmacology, 2001-08, Vol.41 (8), p.870-879

2001

Volltextzugriff (PDF)

Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agentsa

Annals of the New York Academy of Sciences, 1991-02, Vol.614 (1), p.193-213

1991

Volltextzugriff (PDF)

CONTRIBUTING PHARMACOLOGIC FACTORS IN MORPHINE-INDUCED FETAL MALFORMATIONS

IULIUCCI, JOHN DOMENIC

1973

Volltextzugriff (PDF)

Morphine-Induced Fetal Malformations II: Influence of Histamine and Diphenhydramine

Journal of pharmaceutical sciences, 1971-03, Vol.60 (3), p.420-425

1971

Volltextzugriff (PDF)

High-Resolution Solid-State NMR Spectroscopy: Characterization of Polymorphism in Cimetidine, a Pharmaceutical Compound

Journal of chemical education, 2014-08, Vol.91 (8), p.1236-1239

2014

Volltextzugriff (PDF)

High-Resolution Solid-State NMR Spectroscopy: Characterization of Polymorphism in Cimetidine, a Pharmaceutical Compound

Journal of chemical education, 2014-08, Vol.91 (8), p.123

2014

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(23)
Dissertationen
(1)

Sprache

Englisch
(24)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

Src Inhibitors in Metastatic Bone Disease

Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model

Structure-Based Design of an Osteoclast-Selective, Nonpeptide Src Homology 2 Inhibitor with in vivo Antiresorptive Activity

Future Anti-Catabolic Therapeutic Targets in Bone Disease

Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit

Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR–ABL including the T315I gatekeeper mutant

Src inhibitors: genomics to therapeutics

Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)

Pharmacologic control of a humanized gene therapy system implanted into nude mice

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML)

SAR of Carbon-Linked, 2-Substituted Purines: Synthesis and Characterization of AP23451 as a novel Bone-Targeted Inhibitor of Src Tyrosine Kinase With In Vivo Anti-Resorptive Activity

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I

Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents

In Vitro and In Vivo Activity of the Src/Abl Kinase Inhibitor AP23464 and Analogs Against Activation Loop Mutants of KIT

Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers

Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agentsa

CONTRIBUTING PHARMACOLOGIC FACTORS IN MORPHINE-INDUCED FETAL MALFORMATIONS

Morphine-Induced Fetal Malformations II: Influence of Histamine and Diphenhydramine

High-Resolution Solid-State NMR Spectroscopy: Characterization of Polymorphism in Cimetidine, a Pharmaceutical Compound

High-Resolution Solid-State NMR Spectroscopy: Characterization of Polymorphism in Cimetidine, a Pharmaceutical Compound

Suchergebnisse filtern